Development of an Antibody Dependent Enhancement(ADE) Assay to Support SARS-CoV2 Vaccine Development


We have developed antibody dependent enhancement (ADE) assay that is capable to evaluating capacity of antibodies to enhance secondary infection with SARS-CoV2 and provide valuable insights into the pathogenesis of this viral infection. This method can play a critical role in development of effective and safe vaccine. The assay is reliable, easy to execute, automation friendly and can be performed in a routine laboratory without the need for a BSL-3 laboratory.